Lu-177 PSMA Therapy — For Advanced Prostate Cancer
Medically reviewed by Dr. Kirti Ranjan Mohanty, Radiation Oncologist (MBBS · MD, Radiation Oncology), Senior Consultant · Last reviewed August 2026
When prostate cancer keeps progressing after hormone-directed treatment, Lu-177 PSMA therapy is one of the options a treating team may raise. This page answers the three questions men and their families actually ask first — who is eligible, how many cycles it takes, and what the side effects are — without hype and without promises.
- Eligibility explained plainly — the scan finding and the blood tests that decide whether this treatment can even reach your disease.
- The full cycle schedule — how many cycles are planned, how far apart, and what is reviewed before each one.
- Side effects, listed honestly — dry mouth, fatigue, blood counts and kidney monitoring — what is common and what needs a call.
- Coordinated, not outsourced — delivered at an NABH-accredited partner nuclear medicine centre, with your CION team managing the plan.
on Panel
Telangana & AP
Treated
(800+ reviews)
What is Lu-177 PSMA therapy?
Lu-177 PSMA therapy is a targeted radioisotope treatment for advanced prostate cancer. A radioactive form of lutetium is attached to a molecule that seeks out PSMA, a protein carried on the surface of most prostate cancer cells. Given as a slow drip, it delivers radiation to cancer deposits throughout the body from the inside.
That is the whole idea in one line: instead of aiming a machine at one area from outside, the radiation travels in the bloodstream and sticks where the cancer is. It belongs to a family of treatments called theranostics — the same target used to see the disease on a scan is the one used to treat it.
This page exists because most of what is written about Lu-177 PSMA online is either a research abstract or marketing copy. Neither answers what a family in Hyderabad actually needs to know before a first appointment. So the three sections below take the three questions in the order they are usually asked: am I eligible, how long does this go on for, and what will it do to me.
Lu-177 PSMA therapy is delivered at an NABH-accredited partner nuclear medicine centre; CION Cancer Clinics coordinates your treatment plan, your oncology team and your care throughout. CION does not own or operate a nuclear medicine facility, a linear accelerator or any other radiotherapy equipment.
Did you know?
PSMA is not a tumour marker in your blood report — it is a protein sitting on the outside surface of most prostate cancer cells. That is why the PSMA PET-CT scan is used twice over in this treatment: first to find out whether your disease can be reached at all, and then as the map the therapy follows.
Who is eligible for Lu-177 PSMA therapy?
Eligibility is decided case by case, not by request. In broad terms it is considered for men with metastatic prostate cancer that has kept progressing despite hormone-directed treatment, whose PSMA PET-CT shows the cancer takes up the tracer strongly, and whose kidney function and blood counts are adequate for treatment.
The scan is the part most families do not expect. A PSMA PET-CT is not simply a staging scan here — it is the eligibility test itself. If the deposits do not light up, the therapy has nothing to attach to, and no amount of willingness to pay changes that. This is why a treating team will not commit to the treatment before the scan is done and read.
What a team is usually looking for
- Prostate cancer that has spread beyond the prostate and is still progressing on hormone-directed treatment.
- A recent PSMA PET-CT showing strong tracer uptake across the sites of disease.
- Kidney function within the range your nuclear medicine team accepts, since the isotope clears through the kidneys.
- Blood counts — haemoglobin, white cells and platelets — high enough to tolerate a course.
- Fitness to sit through an infusion and to follow radiation-safety instructions at home afterwards.
- A tumour board or treating team decision, made with your urologist, medical oncologist and nuclear medicine physician together.
What usually makes it unsuitable
- Sites of disease that do not take up the tracer on the PSMA PET-CT, or a mixed picture where major deposits are cold.
- Kidney function or blood counts below the treating centre's threshold, at least until they recover.
- Very poor general fitness, where the burden of travel and infusions outweighs any likely benefit.
- Untreated urgent problems, such as spinal cord compression, that have to be dealt with first.
Guideline bodies including NCCN place this treatment in the advanced, previously treated setting rather than as a first step. It is not an alternative to surgery or to standard radiation for localised prostate cancer.
How many cycles of Lu-177 PSMA therapy will I need?
A full course is usually planned as up to six cycles, given roughly six weeks apart, so the course spans about seven to eight months. Not everyone completes six. Your team reviews scans and blood tests between cycles and stops earlier if the treatment is not helping or your counts have not recovered.
Six is a plan, not a promise. Each cycle is a fresh decision, and the decision is made on your reports rather than on the original number. Here is what one cycle actually involves.
Review before the cycle
Blood counts, kidney function and your symptoms are checked. If anything is below the threshold, the cycle is postponed by a week or two rather than pushed through — that delay is routine, not a setback.
Infusion day
The dose is given as a slow intravenous infusion at the nuclear medicine department of the partner centre. The infusion itself takes well under an hour. You are asked to drink plenty of fluid and to pass urine often, so the isotope that is not taken up clears quickly.
Observation, then discharge
You stay for a few hours of observation and radiation-safety measurement. Most men go home the same day. A short inpatient stay is arranged only if the centre's protocol or your dose requires it.
Precautions at home for a few days
You carry measurable radioactivity for a short period, so you follow written distance, toilet and laundry rules for the number of days your team specifies. These are covered in detail on our household precautions after radioisotope therapy guide.
Assessment, and the decision about the next cycle
Around six weeks later your team reviews blood tests, symptoms and, at set points, imaging. Only then is the next cycle confirmed. Treatment is stopped early if the disease is clearly progressing anyway, or if your counts or kidney function are not recovering.
If you are coordinating for a relative from another city or from abroad, plan around the cycle rhythm rather than a single trip: one hospital day roughly every six weeks, with a few restricted days at home after each.
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Dr. Mohammed Imran
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a second opinion before you commit to a course
A course of radioisotope therapy is a months-long commitment. One review of your scans and reports is free, confidential and carries no obligation to start treatment.
What are the side effects of Lu-177 PSMA therapy?
The most common are a dry mouth, tiredness and mild nausea. Blood counts can fall, because bone marrow near treated deposits receives some radiation. Kidney function is monitored throughout. Most effects are mild to moderate and build slowly across cycles rather than arriving all at once.
| What you may notice | Why it happens | What usually helps |
|---|---|---|
| Dry mouth | Salivary glands also carry some PSMA, so they pick up a share of the dose | Sip fluids through the day, use sugar-free lozenges or chewing gum, and ask your team about a prescribed rinse if it becomes troublesome |
| Fatigue | A general response to radiation delivered through the bloodstream, often worse in the week after a cycle | Short walks rather than bed rest, protected sleep, and planning your commitments around the first week of each cycle |
| Nausea, reduced appetite | A common early effect in the days after an infusion | Small frequent meals, and an anti-sickness medicine if your team prescribes one |
| Falling blood counts | Bone marrow close to treated bone deposits receives radiation, so haemoglobin, white cells or platelets can drop | Blood tests before every cycle; a cycle is delayed if counts have not recovered, and unusual bruising, bleeding or fever is reported the same day |
| Kidney function changes | The isotope clears through the kidneys, so they receive a share of the dose | Good fluid intake around each cycle and routine kidney blood tests through the course |
| A short flare of bone pain | Treated bone deposits can become briefly more painful in the first days after a cycle | Tell your team before the cycle if you already have bone pain, so pain control is planned rather than improvised |
This list is what is commonly reported and discussed in ASTRO and NCCN patient guidance. It is not exhaustive, and your written consent discussion at the partner centre is where the full list for your dose is covered. Call your team the same day for fever, bleeding, sudden severe pain, or a drop in how much urine you are passing.
Am I radioactive after each cycle?
For a short period, yes. Unlike external beam radiation, this treatment leaves measurable radioactivity in your body for a few days, most of it clearing through urine. Your team gives you written, dose-specific rules on toilet use, laundry, sleeping and distance from young children and pregnant family members.
This is the single biggest practical difference between radioisotope therapy and the daily radiation most people picture. There is no machine and no mask, but there is a short window at home where distance matters. The rules are simple, they are temporary, and they are written down with dates — follow those dates rather than a general figure from a forum.
Depending on the centre's protocol and your dose, you may be observed in a dedicated shielded room before discharge. Our guide to the isolation room stay during radioisotope therapy covers what that room is like and what to carry, and living with someone after radioisotope therapy covers the household rules once you are home.
Attendants and family members are not at risk when they follow the written distance and hygiene instructions. Ask the nuclear medicine team to explain the sheet to whoever will actually be at home with you, not only to the patient.
How is Lu-177 PSMA therapy arranged in Hyderabad?
It is a specialised service, not a routine one. Your therapy is delivered at an NABH-accredited partner nuclear medicine centre holding the required regulatory licence, while CION Cancer Clinics coordinates your treatment plan, your oncology team and your care throughout the course.
In practice, the sequence is: a consultation and record review, a PSMA PET-CT at a partner imaging centre, a treating-team decision on eligibility, and then a scheduled first cycle. Slot availability depends on scan bookings and on isotope stock at the partner centre, so dates are confirmed rather than assumed — ask for them in writing.
If you are coordinating from outside Hyderabad
Families arranging care for a father or brother from another city, or from overseas, usually want to know how much travel is unavoidable. Scan reports and prior records can be reviewed remotely before anyone books a ticket, which means the eligibility conversation happens before the journey rather than after it. Once a course starts, plan one hospital day roughly every six weeks, with a few restricted days at home after each cycle.
What about cost?
Radioisotope therapy is quoted per cycle rather than as a single package, and the PSMA PET-CT scans are billed separately from the treatment itself. Because the number of cycles you actually receive is reviewed as you go, the total is a range, not a fixed figure. Any estimate you are given is indicative, as of August 2026, and shifts with the centre, the scan protocol and stock availability. Our page on the cost of theranostics and radioisotope therapy in India sets out what an itemised estimate should contain and what insurance and government schemes typically do and do not cover.
Ask for a written, itemised estimate naming what is included — scans, infusion, room, monitoring, follow-up — before you commit to a course.
One conversation tells you where you actually stand
Whether Lu-177 PSMA therapy fits your case or another route makes more sense, you deserve a clear answer from a team that has seen advanced prostate cancer before.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Lu-177 PSMA therapy — your questions answered
Who is eligible for Lu-177 PSMA therapy?
Eligibility is decided case by case by a treating team, not on request. It is generally considered for men with metastatic prostate cancer that has kept progressing despite hormone-directed treatment, and often after chemotherapy. A PSMA PET-CT scan has to show that the disease takes up the tracer strongly, because only deposits that light up on that scan can be reached by the therapy. Kidney function, bone marrow reserve and blood counts also have to be adequate. Men whose scan shows areas of disease that do not take up the tracer are usually advised a different route.
How many cycles of Lu-177 PSMA therapy will I need?
A full course is usually planned as up to six cycles, given roughly six weeks apart, so the course spans about seven to eight months. Not everyone completes six. Your team reviews your scans, symptoms and blood tests before each cycle and stops earlier if the treatment does not appear to be helping, or if your blood counts or kidney function have not recovered enough. A smaller number of patients are offered further cycles later. The number is a plan, not a promise, and it is revisited at every review.
What are the side effects of Lu-177 PSMA therapy?
The most commonly reported effects are a dry mouth, tiredness and mild nausea. Blood counts can fall, because bone marrow close to treated deposits receives some radiation, so counts are checked before every cycle. Kidney function is monitored throughout the course. Some men notice a short-lived increase in bone pain in the first days after a cycle. Most effects are mild to moderate and build gradually across cycles rather than arriving all at once. Your team gives you written instructions on what to watch for and when to call.
Is Lu-177 PSMA therapy available in India?
Yes. It is delivered at a small number of licensed nuclear medicine departments in India, including facilities in Hyderabad, and it is a specialised service rather than a routine one. CION Cancer Clinics does not own or operate a nuclear medicine facility or any radiotherapy machine. Your therapy is delivered at an NABH-accredited partner centre with the required regulatory licence, while CION coordinates your treatment plan, your oncology team and your care throughout. Waiting times depend on scan slots and on stock availability at the partner centre.
Am I radioactive after Lu-177 PSMA therapy?
For a short period, yes. Unlike external beam radiation, this treatment leaves measurable radioactivity in your body for a few days, most of which clears through urine. Your nuclear medicine team gives you written, dose-specific precautions covering toilet use, laundry, sleeping arrangements and distance from young children and pregnant family members. These usually apply for a small number of days after each cycle. Follow the written dates you are given rather than a general estimate you read online.
What does Lu-177 PSMA therapy cost in India?
It is quoted per cycle rather than as one package price, so the cost of a course depends on how many cycles you actually receive, and the PSMA PET-CT scans before and during treatment are billed separately. Any figure you are given is indicative, as of August 2026, and changes with the centre, the scan protocol and stock availability. Ask for a written, itemised estimate that names what is and is not included before you commit, and check what your insurance or scheme will cover.
This page is a general explainer about Lu-177 PSMA therapy, not medical advice and not a recommendation for your case. Only your treating oncology and nuclear medicine team, working from your own scans and blood tests, can say whether this treatment is an option for you.